Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin

February 19, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search